Successful treatment of central nervous system involved Erdheim–Chester disease by intermediate-dose cytarabine as first-line therapy

References

• Cavalli G, Guglielmi B, Berti A, et al. The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 2013;72(10):1691–1695.
   PubMed Web of Science ®Google Scholar
• Cao X, Sun J, Li J, et al. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol. 2016;95(5):745–750.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483–492.
   PubMed Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–2703.
   PubMed Web of Science ®Google Scholar
• Cao X-X, Niu N, Sun J, et al. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim–Chester disease. Orphanet J Rare Dis. 2019;14(1):11.
   PubMedGoogle Scholar
• Haroche J, Cohen-Aubart F, Emile J-F, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease. J Clin Oncol. 2015;33(5):411–418.
   PubMed Web of Science ®Google Scholar
• Braiteh F, Boxrud C, Esmaeli B, et al. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106(9):2992–2994.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778–2782.
   PubMed Web of Science ®Google Scholar
• Allen CE, Ladisch S, Mcclain KL. How I treat Langerhans cell histiocytosis. Blood. 2015;126(1):26–35.
   PubMed Web of Science ®Google Scholar
• Maintz L, Wenzel J, Irnich M, et al. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2‐chlorodeoxyadenosine: case report and review of the literature. Br J Dermatol. 2017;176(2):481–487.
   PubMed Web of Science ®Google Scholar
• Cao X, Niu N, Sun J, et al. Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease. Ann Hematol. 2018;97(1):185–187.
   PubMed Web of Science ®Google Scholar
• Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim–Chester Disease. Curr Rheumatol Rep. 2014;16(4):412.
   PubMed Web of Science ®Google Scholar
• Drier A, Haroche J, Savatovsky J, et al. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology. 2010;255(2):586–594.
   PubMed Web of Science ®Google Scholar
• Hervier B, Arnaud L, Charlotte F, et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-α. Semin Arthritis Rheum. 2012;41(6):907.
   PubMed Web of Science ®Google Scholar
• Fioravanti J, Medina-Echeverz J, Ardaiz N, et al. The fusion protein of IFN-α and apolipoprotein A-I crosses the blood–brain barrier by a saturable transport mechanism. J Immunol. 2012;188(8):3988–3992.
   PubMed Web of Science ®Google Scholar
• Aubart FC, Emile J, Maksud P, et al. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease. Br J Haematol. 2018;180(1):150–153.
   PubMed Web of Science ®Google Scholar
• Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116(20):4070–4076.
   PubMed Web of Science ®Google Scholar
• Slevin M, Piall E, Aherne G, et al. The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high‐dose therapy. Med Pediatr Oncol. 1982;10(S1):157–168.
   PubMedGoogle Scholar
• Simko SJ, McClain KL, Allen CE. Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone? Br J Haematol. 2015;169(2):299.
   PubMed Web of Science ®Google Scholar